2019
Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.
Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.Peer-Reviewed Original ResearchFemale breast cancer patientsBreast cancer patientsNCCN criteriaCancer patientsGenetic counselingHigher breast cancer mortality ratesYounger ageHBOC testingBreast cancer mortality ratesOvarian cancer syndromeBreast cancer treatmentBreast cancer casesCancer mortality ratesYears of ageTesting servicesFurther genetic counselingPre-test counselingBreast cancer diagnosisNCCN guidelinesChart reviewFemale patientsOncology unitBreast cancerCancer casesFamily history
2013
Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer.
Sorkin M, Lapolt D, Pusztai L, Hofstatter E. Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer. Journal Of Clinical Oncology 2013, 31: 1565-1565. DOI: 10.1200/jco.2013.31.15_suppl.1565.Peer-Reviewed Original ResearchCancer prevention clinicPostmenopausal womenPrevention clinicBreast cancerRetrospective chart reviewPoor patient acceptancePatient acceptance rateRisk of thrombosisCancer chemoprevention agentsBreast atypiaChemoprevention medicationsChemoprevention uptakeChart reviewEligible womenPatient characteristicsPrevention settingMedication uptakeMean ageChemoprevention agentsMedical historyUterine cancerPatient acceptanceFamily historyGeneral populationExemestane